ROCKET PHARMACEUTICALS, INC.
For the period ended Mar 26, 2026. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 26, 2026 · Filed Mar 27, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Interference with Serology Testing
Interference with Serology Testing
Patients who have received KRESLADI are likely to test positive by polymerase chain reaction (PCR) assays for HIV due to LVV provirus insertion resulting in a false-positive test for HIV. Therefore, patients who have received KRESLADI should not be screened for HIV infection using a PCR-based assay.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.